The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Open accessAbstract
Activating receptor tyrosine kinase RET (rarranged during transfection) gene alterations have been identified as oncogenic in multiple malignancies. RET gene rearrangements retaining the kinase domain are oncogenic drivers in papillary thyroid cancer, non–small-cell lung cancer, and multiple other cancers. Activating RET mutations are associated with different phenotypes of multiple endocrine neoplasia type 2 as well as sporadic medullary thyroid cancer. RET is thus an attractive therapeutic target in patients with oncogenic RET alterations. Multikinase inhibitors with RET inhibitor activity, such as cabozantinib and vandetanib, have been explored in the clinic for tumors with activating RET gene alterations with modest clinical efficacy. As a result of the nonselective nature of these multikinase inhibitors, patients had off-target adverse effects, such as hypertension, rash, and diarrhea. This resulted in a narrow therapeutic index of these drugs, limiting ability to dose for clinically effective RET inhibition. In contrast, the recent discovery and clinical validation of highly potent selective RET inhibitors (pralsetinib, selpercatinib) demonstrating improved efficacy and a more favorable toxicity profile are poised to alter the landscape of RET-dependent cancers. These drugs appear to have broad activity across tumors with activating RET alterations. The mechanisms of resistance to these next-generation highly selective RET inhibitors is an area of active research. This review summarizes the current understanding of RET alterations and the state-of-the-art treatment strategies in RET-dependent cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Wells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret
Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F., & Pachnis, V. (1994) · Nature · doi:10.1038/367380a0 · Cited by 1,614
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., Qian, F., Chu, F., Bentzien, F., Cancilla, B., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0264 · Cited by 1,336
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Grieco, M., Santoro, M., Berlingieri, M. T., Melillo, R. M., Donghi, R., Bongarzone, I., Pierotti, M. A., Della Ports, G., Fusco, A., & Vecchiot, G. (1990) · Cell · doi:10.1016/0092-8674(90)90659-3 · Cited by 959
Activation of a novel human transforming gene, ret, by DNA rearrangement
Takahashi, M., Ritz, J., & Cooper, G. M. (1985) · Cell · doi:10.1016/0092-8674(85)90115-1 · Cited by 854
Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B
Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. (1995) · Science · doi:10.1126/science.7824936 · Cited by 841
Expression of the c-ret proto-oncogene during mouse embryogenesis
Pachnis, V., Mankoo, B., & Costantini, F. (1993) · Development · doi:10.1242/dev.119.4.1005 · Cited by 837
KIF5B-RET fusions in lung adenocarcinoma
Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2644 · Cited by 834
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D., Kwok, J. B. J., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 652
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
Wiesner, T., He, J., Yelensky, R., Esteve-Puig, R., Botton, T., Yeh, I., Lipson, D., Otto, G., Brennan, K., Murali, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4116 · Cited by 649
Carlomagno, F., Vitagliano, D., Guida, T., Ciardiello, F., Tortora, G., Vecchio, G., Ryan, A. J., Fontanini, G., Fusco, A., & Santoro, M. M. (2002) · PubMed · Cited by 569
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
Wang, R., Hu, H., Pan, Y., Li, Y., Ye, T., Li, C., Luo, X., Wang, L., Li, H., Zhang, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1477 · Cited by 546
Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1714 · Cited by 531
Camidge, D. R., Dziadziuszko, R., Peters, S., Mok, T., Noe, J., Nowicka, M., Gadgeel, S. M., Cheema, P., Pavlakis, N., de Marinis, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.03.007 · Cited by 490
Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, S., Bleazard, T., Won, J.-K., Kim, Y. T., Kim, J.-I., Kang, J.-H., & Seo, J.-S. (2012) · Genome Research · doi:10.1101/gr.133645.111 · Cited by 484
Drilon, A., Rekhtman, N., Arcila, M., Wang, L., Ni, A., Albano, M., Van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30562-9 · Cited by 484
Self-citationBenayed, R., Offin, M., Mullaney, K., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R., Won, H., Chang, J., Halpenny, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0225 · Cited by 484
Self-citationRET tyrosine kinase signaling in development and cancer
Arighi, E., Borrello, M. G., & Sariola, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.010 · Cited by 468
Takahashi, M., Buma, Y., Iwamoto, T., Inaguma, Y., Ikeda, H., & Hiai, H. (1988) · PubMed · Cited by 442
Piotrowska, Z., Isozaki, H., Lennerz, J. K., Gainor, J. F., Lennes, I. T., Zhu, V. W., Marcoux, N., Banwait, M. K., Digumarthy, S. R., Su, W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1022 · Cited by 442
Rabes, H. M., Demidchik, E. P., Sidorow, J. D., Lengfelder, E., Beimfohr, C., Hoelzel, D., & Klugbauer, S. (2000) · PubMed · Cited by 428
Selective RET kinase inhibition for patients with RET-altered cancers
Subbiah, V., Velcheti, V., Tuch, B. B., Ebata, K., Busaidy, N. L., Cabanillas, M. E., Wirth, L. J., Stock, S., Smith, S., Lauriault, V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy137 · Cited by 425
Self-citationA new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases
Fusco, A., Grieco, M., Santoro, M., Berlingieri, M. T., Pilotti, S., Pierotti, M. A., Porta, G. D., & Vecchio, G. (1987) · Nature · doi:10.1038/328170a0 · Cited by 413
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Drilon, A., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.175 · Cited by 406
Self-citationPrecision Targeted Therapy with BLU-667 for RET-Driven Cancers
Subbiah, V., Gainor, J. F., Rahal, R., Brubaker, J. D., Kim, J. L., Maynard, M., Hu, W., Cao, Q., Sheets, M. P., Wilson, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0338 · Cited by 396
Self-citationLiu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A
Skinner, M. A., Moley, J. A., Dilley, W. G., Owzar, K., DeBenedetti, M. K., & Wells, S. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043999 · Cited by 381
Leboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., Gómez, J. M., Bonichon, F., Leenhardt, L., Soufflet, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70335-2 · Cited by 375
Santoro, M. M., Dathan, N. A., Berlingieri, M. T., Bongarzone, I., Paulin, C., Grieco, M., Pierotti, M. A., Vecchio, G., & Fusco, A. (1994) · PubMed · Cited by 366
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.9352 · Cited by 360
Self-citationA comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Romei, C., Ciampi, R., & Elisei, R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.11 · Cited by 352
Mechanism of Activation of the ret Proto-oncogene by Multiple Endocrine Neoplasia 2A Mutations
Asai, N., Iwashita, T., Matsuyama, M., & Takahashi, M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.3.1613 · Cited by 340
Castellanos, E., Feld, E., & Horn, L. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.014 · Cited by 313
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain
Knowles, P. P., Murray-Rust, J., Kjær, S., Scott, R. P., Hanrahan, S., Santoro, M., Ibáñez, C. F., & McDonald, N. Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605604200 · Cited by 302
Yoh, K., Seto, T., Satouchi, M., Nishio, M., Yamamoto, N., Murakami, H., Nogami, N., Matsumoto, S., Kohno, T., Tsuta, K., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30322-8 · Cited by 294
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 282
Self-citationElisei, R., Romei, C., Vorontsova, T., Cosci, B., Veremeychik, V., Kuchinskaya, E., Basolo, F., Demidchik, E. P., Miccoli, P., Pinchera, A., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7678 · Cited by 275
The Role of GDNF/Ret Signaling in Ureteric Bud Cell Fate and Branching Morphogenesis
Shakya, R., Watanabe, T., & Costantini, F. (2005) · Developmental Cell · doi:10.1016/j.devcel.2004.11.008 · Cited by 268
Carlomagno, F., Guida, T., Anaganti, S., Vecchio, G., Fusco, A., Ryan, A. J., Billaud, M., & Santoro, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207810 · Cited by 258
Agrawal, N., Jiao, Y., Sausen, M., Leary, R., Bettegowda, C., Roberts, N. J., Bhan, S., Ho, A. S., Khan, Z., Bishop, J., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2703 · Cited by 255
Besset, V., Scott, R. P., & Ibáñez, C. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006908200 · Cited by 255
Schlumberger, M., Jarzab, B., Cabanillas, M. E., Robinson, B., Pacini, F., Ball, D. W., McCaffrey, J., Newbold, K., Allison, R., Martins, R. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1127 · Cited by 247
Lee, S.-H., Lee, J.-K., Ahn, M.-J., Kim, D.-W., Sun, J.-M., Keam, B., Kim, T. M., Heo, D. S., Ahn, J. S., Choi, Y.-L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw559 · Cited by 244
Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers
Ricarte-Filho, J. C., Li, S., Garcia-Rendueles, M. E. R., Montero-Conde, C., Voza, F., Knauf, J. A., Heguy, A., Viale, A., Bogdanova, T., Thomas, G. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69766 · Cited by 241
Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M. C., Niederle, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx479 · Cited by 240
Gimm, O. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.11.3902 · Cited by 237
Berndt, I., Reuter, M., Saller, B., Frank-Raue, K., Groth, P., Grußendorf, M., Raue, F., Ritter, M. M., & Höppner, W. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4619 · Cited by 229
Hayashi, H., Ichihara, M., Iwashita, T., Murakami, H., Shimono, Y., Kawai, K., Kurokawa, K., Murakumo, Y., Imai, T., Funahashi, H., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203799 · Cited by 223
RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
Tsuta, K., Kohno, T., Yoshida, A., Shimada, Y., Asamura, H., Furuta, K., & Kushima, R. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.36 · Cited by 202
Cooperation between GDNF/Ret and ephrinA/EphA4 Signals for Motor-Axon Pathway Selection in the Limb
Kramer, E. R., Knott, L., Su, F., Dessaud, E., Krull, C. E., Helmbacher, F., & Klein, R. (2006) · Neuron · doi:10.1016/j.neuron.2006.02.020 · Cited by 195
Anders, J., Kjær, S., & Ibáñez, C. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104968200 · Cited by 163
Hamatani, K., Eguchi, H., Ito, R., Mukai, M., Takahashi, K., Taga, M., Imai, K., Cologne, J., Soda, M., Arihiro, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0293 · Cited by 160
Liu, X., Vega, Q. C., Decker, R. A., Pandey, A., Worby, C. A., & Dixon, J. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5309 · Cited by 160
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
Offin, M. D., Guo, R., Wu, S. L., Sabari, J. K., Land, J. D., Ni, A., Montecalvo, J., Halpenny, D. F., Buie, L. W., Pak, T., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00386 · Cited by 151
Self-citationFrequent association between MEN 2A and cutaneous lichen amyloidosis
Verga, U., Fugazzola, L., Cambiaghi, S., et al. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01782.x · Cited by 145
Frank‐Raue, K., Höppner, W., Frilling, A., Kotzerke, J., Dralle, H., Haase, R., Mann, K., Seif, F., Kirchner, R., Rendl, J., et al. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.5.1780 · Cited by 141
Eph receptors and ephrins as targets for cancer therapy
Xi, H., Wu, X., Wei, B., & Chen, L. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01612.x · Cited by 138
Jain, S. R., Naughton, C. K., Yang, M., Strickland, A. M., Vij, K. R., Encinas, M., Golden, J., Gupta, A. K., Heuckeroth, R. O., Johnson, E. M., et al. (2004) · Development · doi:10.1242/dev.01421 · Cited by 136
Frank‐Raue, K., Buhr, H. J., Dralle, H., Klar, E., Senninger, N. J., Weber, T., Rondot, S., Höppner, W., & Raue, F. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02216 · Cited by 130
Romei, C., Cosci, B., Renzini, G., Bottici, V., Molinaro, E., Agate, L., Passannanti, P., Viola, D., Biagini, A., Basolo, F., et al. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03900.x · Cited by 127
Central Role of RET in Thyroid Cancer
Santoro, M. M., & Carlomagno, F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009233 · Cited by 126
Concomitant RAS , RET/PTC , or BRAF Mutations in Advanced Stage of Papillary Thyroid Carcinoma
Zou, M., Baitei, E. Y., Alzahrani, A. S., BinHumaid, F. S., Alkhafaji, D., Al‐Rijjal, R. A., Meyer, B. F., & Shi, Y. (2014) · Thyroid · doi:10.1089/thy.2013.0610 · Cited by 126
The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function
Fonseca‐Pereira, D., Arroz‐Madeira, S., Rodrigues-Campos, M., Barbosa, I. A. M., Domingues, R. G., Bento, T., Almeida, A. R. M., Ribeiro, H., Potocnik, A. J., Enomoto, H., et al. (2014) · Nature · doi:10.1038/nature13498 · Cited by 120
RAS proto-oncogene in medullary thyroid carcinoma
Moura, M. M., Cavaco, B. M., & Leite, V. A. P. H. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0070 · Cited by 119
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Drilon, A. E. D. C., Fu, S., Patel, M. R., Fakih, M., Wang, D., Olszanski, A. J., Morgensztern, D., Liu, S. V., Cho, B. C., Bazhenova, L. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0839 · Cited by 116
Self-citationRavaud, A., de la Fouchardière, C., Caron, P. J., Doussau, A., Cao, C. D., Asselineau, J., Rodien, P., Pouessel, D., Nicolli-Sire, P., Klein, M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.029 · Cited by 115
Identification and characterization of RET fusions in advanced colorectal cancer
Rolle, A.-F. L., Klempner, S. J., Garrett, C. R., Seery, T. E., Sanford, E. M., Balasubramanian, S., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4325 · Cited by 113
Tyrosine 981, a Novel Ret Autophosphorylation Site, Binds c-Src to Mediate Neuronal Survival
Encinas, M., Crowder, R. J., Milbrandt, J., & Johnson, E. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400505200 · Cited by 113
MEN2A-RET-induced cellular transformation by activation of STAT3
Schuringa, J. J., Wojtachnio, K., Hagens, W. I., Vellenga, E., Buys, C. H. C. M., Hofstra, R. M. W., & Kruijer, W. (2001) · Oncogene · doi:10.1038/sj.onc.1204715 · Cited by 109
A secondary RET mutation in the activation loop conferring resistance to vandetanib
Nakaoku, T., Kohno, T., Araki, M., Niho, S., Chauhan, R., Knowles, P. P., Tsuchihara, K., Matsumoto, S., Shimada, Y., Mimaki, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02994-7 · Cited by 108
Ballerini, P. F., Struski, S., Cresson, C., Prade, N., Toujani, S., Deswarte, C., Dobbelstein, S., Petit, A., Lapillonne, H., Gautier, E., et al. (2012) · Leukemia · doi:10.1038/leu.2012.109 · Cited by 107
Worby, C. A., Vega, Q. C., Chao, H. H.-J., Seasholtz, A. F., Thompson, R. C., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.6.3502 · Cited by 105
Drilon, A. E. D. C., Subbiah, V., Oxnard, G. R., Bauer, T. M., Velcheti, V., Lakhani, N. J., Besse, B., Park, K., Patel, J. D., Cabanillas, M. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.102 · Cited by 104
Self-citationHassani, R. A. E., Boufraqech, M., Chevallier, O., Weyemi, U., Talbot, M., Métivier, D., Courtin, F., Bidart, J., Mzibri, M. E., Schlumberger, M. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4336 · Cited by 103
Carney Complex: Pathology and Molecular Genetics
Boikos, S. A., & Stratakis, C. A. (2006) · Neuroendocrinology · doi:10.1159/000095527 · Cited by 101
DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells
Gandhi, M., Dillon, L. W., Pramanik, S., Nikiforov, Y. E., & Wang, Y.-H. (2010) · Oncogene · doi:10.1038/onc.2009.502 · Cited by 98
Takahashi, M., Iwashita, T., Santoro, M. M., Lyonnet, S., Lenoir, G., & Billaud, M. (1999) · Human Mutation · Cited by 91
Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations
Rossel, M., Pasini, A., Chappius, S., Geneste, O., Fournier, L., Schuffenecker, I., Takahishi, M., van Grunsven, L. A., Urdiales, J. L., Rudkin, B. B., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1200831 · Cited by 89
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
Mologni, L., Redaelli, S., Morandi, A., Plaza-Menacho, I., & Gambacorti-Passerini, C. B. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.06.025 · Cited by 87
Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study
NGUYEN, L. T. H., Niccoli‐Sire, P., Caron, P. J., et al. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440037 · Cited by 85
RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer
Blaugrund, J. E., Johns, M. M. E., Eby, Y. J., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.10.1895 · Cited by 84
Gould, T. W., Yonemura, S., Oppenheim, R. W., Ohmori, S., & Enomoto, H. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.5185-07.2008 · Cited by 83
Nelson-Taylor, S. K., Le, A. T., Yoo, M., Schubert, L., Mishall, K. M., Doak, A. E., Varella‐Garcia, M., Tan, A. C., & Doebele, R. C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0008 · Cited by 83
Wells, S. A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0325 · Cited by 79
Jasim, S., Ying, A. K., Waguespack, S. G., et al. (2010) · Thyroid · doi:10.1089/thy.2010.0328 · Cited by 77
Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma
Huang, Q., Schneeberger, V. E., Luetteke, N., Jin, C., Afzal, R., Budzevich, M. M., Makanji, R. J., Martinez, G. V., Shen, T., Zhao, L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0258 · Cited by 77
Subbiah, V., Berry, J., Roxas, M., Guha‐Thakurta, N., Subbiah, I. M., Ali, S. M., McMahon, C., Miller, V. A., Cascone, T., Pai, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.04.004 · Cited by 71
Self-citationGoodman, K. M., Kjær, S., Beuron, F., Knowles, P. P., Nawrotek, A., Burns, E. M., Purkiss, A. G., George, R., Santoro, M., Morris, E. P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.040 · Cited by 69
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
Facchinetti, F., Rossi, G., Bria, E., Soria, J., Besse, B., Minari, R., Friboulet, L., & Tiseo, M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.010 · Cited by 69
KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer
Qian, Y., Chai, S., Liang, Z., Wang, Y., Zhou, Y., Xu, X., Zhang, C., Zhang, M., Si, J., Huang, F., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-176 · Cited by 67
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
Plenker, D., Riedel, M., Brägelmann, J., Dammert, M. A., Chauhan, R., Knowles, P. P., Lorenz, C., Keul, M., Bührmann, M., Pagel, O., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah6144 · Cited by 67
Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma
Mizukami, T., Shiraishi, K., Shimada, Y., Ogiwara, H., Tsuta, K., Ichikawa, H., Sakamoto, H., Kato, M., Shibata, T., Nakano, T., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000135 · Cited by 66
Guerra, A., Zeppa, P., Bifulco, M., & Vitale, M. (2013) · Thyroid · doi:10.1089/thy.2013.0235 · Cited by 64
Structure and function of RET in multiple endocrine neoplasia type 2
Plaza-Menacho, I. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0354 · Cited by 57
Perrinjaquet, M., Vilar, M., & Ibáñez, C. F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.144923 · Cited by 53
An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
Lim, S. M., Chung, W. Y., Nam, K., Kang, S., Lim, J. Y., Kim, H., Shin, S. H., Sun, J.-M., Kim, S.-G., Kim, J.-H., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.020 · Cited by 50
EGF Induced RET Inhibitor Resistance inCCDC6-RETLung Cancer Cells
Chang, H. K., Sung, J. H., Moon, S. U., Kim, H.-S., Kim, J. W., & Lee, J. S. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.1.9 · Cited by 42
Taylor, M. H., Gainor, J. F., Hu, M. I.-N., Zhu, V. W., Junior, G. L. L., Leboulleux, S., Brose, M. S., Schüler, M., Bowles, D. W., Kim, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.6018 · Cited by 42
Self-citationRelative Expression of the RET9 and RET51 Isoforms in Human Pheochromocytomas
Hir, H. L., Charlet‐Berguerand, N., Gimenez‐Roqueplo, A., Mannelli, M., Plouin, P., de Franciscis, V., & Thermes, C. (2000) · Oncology · doi:10.1159/000012118 · Cited by 37
Functional characterization of a novel FGFR1OP‐RET rearrangement in hematopoietic malignancies
Bossi, D., Carlomagno, F., Pallavicini, I., Pruneri, G., Trubia, M., Raviele, P. R., Marinelli, A., Anaganti, S., Cox, M. C., Viale, G., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.11.004 · Cited by 33
Schöffski, P., Aftimos, P. G., Massard, C., Italiano, A., Jungels, C., Andreas, K., Keegan, M., & Ho, P. T. C. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps3162 · Cited by 32
Griseri, P., Garrone, O., Sardo, A. L., Monteverde, M., Rusmini, M., Tonissi, F., Merlano, M. C., Bruzzi, P., Nigro, C. L., & Ceccherini, I. (2016) · Oncotarget · doi:10.18632/oncotarget.8417 · Cited by 29
Caccese, M., Ferrara, R., Pilotto, S., Carbognin, L., Grizzi, G., Caliò, A., Brunelli, M., Cuppone, F., Petraglia, S., Scarpa, A., et al. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1242578 · Cited by 27
Multiple endocrine neoplasia type 2 syndromes: historical perspectives.
Sipple, J. H. (1984) · PubMed · Cited by 25
Seki, Y., Mizukami, T., & Kohno, T. (2015) · Biomolecules · doi:10.3390/biom5042464 · Cited by 21
Cited by
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Gainor, J. F., Curigliano, G., Kim, D.-W., Lee, D. H., Besse, B., Baik, C. S., Doebele, R. C., Cassier, P. A., Lopes, G., Tan, D. S. W., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00247-3 · Cited by 440
Self-citationSubbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00120-0 · Cited by 366
Self-citationTargeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity
Yu, Y., Liu, A., Dhawan, G., Mei, H., Zhang, W., Izawa, K., Soloshonok, V. A., & Han, J. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.05.042 · Cited by 182
Metadata
- Authors
- Subbiah, V., Yang, D., Velcheti, V., Drilon, A., & Meric-Bernstam, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-04-10
- Volume
- 38
- Issue
- 11
- Pages
- 1209-1221
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3008903497
- Cited by
- 258
- References
- 116
- FWCI
- 25.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.